Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Cryptotanshinone for preventing and treating pulmonary fibrosis and application thereof

A technology for cryptotanshinone and pulmonary fibrosis, which is applied in the field of medicine and can solve problems such as the absence of cryptotanshinone

Inactive Publication Date: 2017-06-06
SUN YAT SEN UNIV +1
View PDF3 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, no use of cryptotanshinone as a treatment for pulmonary fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cryptotanshinone for preventing and treating pulmonary fibrosis and application thereof
  • Cryptotanshinone for preventing and treating pulmonary fibrosis and application thereof
  • Cryptotanshinone for preventing and treating pulmonary fibrosis and application thereof

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0025] Experimental example 1 The effect of cryptotanshinone on the proliferation of human embryonic lung fibroblast (HLF) cells:

[0026] (1) Experimental materials: HLF cells were purchased from the Experimental Animal Center of Sun Yat-sen University. DMEM medium (Gibco, USA), fetal bovine serum-like (Hyclone, USA), MTT (Sigma);

[0027] (2) Experiment method: 5.0×10 3 The HLF cells were added to the wells of a 96-well plate and cultured for 24 h. Aspirate the original culture solution, add the complete culture solution containing different concentrations (2.5 μM, 5 μM, 10 μM, 20 μM) of cryptotanshinone, and add the complete culture solution without cryptotanshinone as a normal control. Continue to culture for 48 h, add 20 μL of phosphate-buffered saline containing 5 mg / mL MTT to each well, after 4 h of culture, aspirate the culture medium in each well, and add 200 μL of dimethyl sulfoxide (DMSO ). Shake for 15 min, at a wavelength of 490 nm, detect the absorbance value...

experiment example 2

[0031] Experimental Example 2 The effect of cryptotanshinone on the abnormal activation of human embryonic lung fibroblast (HLF) cells stimulated by TGF-β1:

[0032] (1) Experimental materials: HLF cells were purchased from the Experimental Animal Center of Sun Yat-sen University. DMEM medium (Gibco, USA), fetal bovine serum-like (Hyclone, USA), human transforming growth factor-β1 (HumanTGF-β1, PeproTech Inc);

[0033] (2) Experimental method: 5.0×103 HLF cells were added to the wells of a 96-well plate and cultured for 24 hours. Divide lung fibroblasts into:

[0034] TGF-β1 treatment group (5 ng / mL action time 48 h); TGF-β1 treatment group (5 ng / mL action time 48 h) + cryptotanshinone 2.5 μM; TGF-β1 treatment group (5 ng / mL action time 48 h) + Cryptotanshinone 5 μM; TGF-β1 treatment group (5 ng / mL for 48 h) + cryptotanshinone 10 μM. TGF-β1 treatment group (5 ng / mL for 48 h) + cryptotanshinone 20 μM. After 48h, BrdU was used to detect cell proliferation. Taking the TGF-β1...

experiment example 3

[0040] Experimental Example 3 The effect of cryptotanshinone on the expression of fibrin in lung fibroblasts stimulated by TGF-β1:

[0041] (1) Materials and methods: HLF cells were purchased from the Experimental Animal Center of Sun Yat-sen University;

[0042] DMEM medium (Gibco, USA), human transforming growth factor-β1 (HumanTGF-β1, PeproTech Inc), α-SMA antibody (Boster Company), mouse secondary antibody (Thermo, USA); trypsin, α-tubulin antibody (Sigma USA ), rabbit secondary antibody (Promega, USA);

[0043] (2) Test method: cells were seeded in 6-well plates and cultured in a cell incubator. When the cells grew confluent to 70-80%, they were starved for 24 h with serum-free medium, and replaced with fresh medium, and the passaged HLF cells were divided into: control group, cryptotanshinone group, cryptotanshinone 25 μM, and the action time was 48 h TGF-β1 Treatment group (5 ng / mL action time 48 h); TGF-β1 treatment group (5 ng / mL action time 48 h) + cryptotanshinone...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medicines, and particularly relates to cryptotanshinone for preventing and treating pulmonary fibrosis and an application thereof. The cryptotanshinone (I) is quinone diterpene extracted from the root part of salviae miltiorrhizae; the modern pharmacological research shows that the cryptotanshinone has a bacteriostatic effect, an anti-inflammatory effect and a hormone-like pharmacologic effect, and is clinically used for treating myocardial fibrosis, lung acute injury and arthritis, can be used for preventing and / or treating a pulmonary fibrosis disease, can also be used for preparing medicines for reducing body weight of a pulmonary fibrosis rat, a lung coefficient and the content of hydroxyproline in tissue and can be used for preparing the medicines for reducing the content of IL-1beta, IL-6 and TNF-alpha in a bronchoalveolar lavage liquid and the medicines of effecting the pathogeny structure of pulmonary fibrosis tissue of the rat. The formula (I) is as shown in the specification.

Description

technical field [0001] The invention relates to the technical field of medicines, in particular to cryptotanshinones for preventing and treating pulmonary fibrosis and applications thereof. Background technique [0002] Pulmonary fibrosis (PF) is a special type of chronic, progressive interstitial pneumonia of unknown etiology. The onset group is 50-70 years old, and it is more common in men than women. The survival rate is low, and the early symptoms are not obvious. The current treatment is mainly to alleviate the condition. [0003] Lung tissue is divided into two parts, the parenchyma and the interstitium. The parenchyma is the place for gas exchange, while the interstitium is the place where pulmonary fibrosis occurs. Allergic reactions, environmental particles, infection, or mechanical damage can lead to disruption of normal tissue architecture. Acutely damaged endothelial cells release inflammatory factors and initiate antifibrinolytic system aggregation. At the s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/343A61P11/00
CPCA61K31/343
Inventor 刘培庆黄民陈健文卢伟婷毕惠嫦陈少锐古练权叶健涛
Owner SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com